Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CuraGen (CRGN) -- Ignore unavailable to you. Want to Upgrade?

To: CrazyPete who wrote (466)	3/30/2007 4:56:20 AM
From: nigel bates	Read Replies (1) \| Respond to of 478

>>Is CRGN so desperate for liquidity...<< Undoubtedly. >>...that this was the best deal they could get?<< I'm sure Roche are very happy indeed. Consolidated revenues for 2007 are expected to range from $50 to $55 million and will likely be earned almost exclusively by 454 Life Sciences. CuraGen's consolidated net loss for 2007 is projected to range from $65 to $70 million, with 454 Life Sciences anticipated to achieve a net income of $1 to $3 million for 2007... >>Well crap.<< Just about sums it up for me.